We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Human immunodeficiency virus [HIV] disease
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
This project will explore the immune and viral correlates of natural control of HIV virus amongst some rare individuals who are able to remain fit and well without taking medicines.
Most people living with HIV need to take medicines every day for the rest of their life in order to control virus infection and keep them well. Rarely some people can control virus without tablets. To help us better understand how they are able to do this we would like to take some extra blood tests to measure the HIV virus and also markers of their immune system.
The aim is to recruit up 25 participants, from three different clinical groups; one group are virus controllers who are not on HIV medicines (from the IDRIS clinic, St Mary’s Hospital, London). Another is people living with HIV who are on antiretroviral treatment for HIV and, who were previously in another study testing an HIV vaccine (RIVER trial). Finally, a control group of people who are HIV negative. They will be asked to attend up to two visits, six months apart where a blood sample will be taken for research. There will also be an initial visit for screening where blood and pregnancy test will be performed.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
a. Currently taking anticoagulants including but not limited to: heparin (Hep-Lock, Hep-Pak), Hep-Pak CVC, Heparin Lock Flush), warfarin (Coumadin), tinzaparin (Innohep), enoxaparin (Lovenox), danaparoid (Orgaran), dalteparin (Fragmin), clopidogrel (Plavix), dipyridamole (Persantine), fondaparinux (Arixtra), argatroban (Agratroban), and bivalrudin (Angiomax). b. Subject taking any of the following medications: systemic steroids (inhaled, nasal, or topical steroid therapy is permitted), interleukins, systemic interferons (e.g. local injection of interferon alpha or use of topical immune modulators for the treatment of HPV is permitted) or systemic chemotherapy. c. Use of any immunomodulatory agents within 30 days prior to study procedure. d. Recipient of a live vaccine within 2 weeks of study procedures. e. Prior recipient of an HIV vaccine. f. Poor venous access. g. Unwilling or unable to comply with study visit requirements. h. Female participant who is pregnant as determined by urine pregnancy test or less than eight weeks post partum. i. On ART (Group 1 and group 3).
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by Imperial College of Science, Technology and Medicine and funded by Bill & Melinda Gates Foundation .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 63664
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
